Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SI-B001 and SI-B003 With or Without Chemotherapy in Advanced NSCLC
NCT05949606Phase 2Active, not recruiting
- Sponsor
- Biokin Pharmaceutical
- Start
- Oct 2023
- Primary completion
- Dec 2026
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of izalontamab, SI-B003 in non-small cell lung cancer (NSCLC), sponsored by Biokin Pharmaceutical. Started Oct 2023; status: active, not recruiting.
02
Drugs
izalontamabSI-B003
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05949606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05949606.